All News

vasculitis.Churg-Strauss_syndrome.wikipedia.jpg

ACR/EULAR 2022 Classification Criteria for EGPA

d Jack Cush, MD

The 2022 ACR/EULAR revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA) have been revised and validated for use in clinical research.

Read Article
ANCA, vasculitis, test

ACR/EULAR 2022 Classification Criteria for Granulomatosis with Polyangiitis

d Jack Cush, MD

The ACR/EULAR 2022 revised classification criteria for granulomatosis with polyangiitis (GPA) have been updated with performance characteristics and are validated for use in clinical research.

Read Article
ANCA, vasculitis, test

ACR/EULAR 2022 Classification Criteria for Microscopic Polyangiitis

d Jack Cush, MD

The 2022 ACR/EULAR  classification criteria for microscopic polyangiitis (MPA) have been developed, validated and are now ready for use in clinical research.

Read Article
gout.podagra_0.jpg

Healthy Diets Prevent Gout in Women

d Jack Cush, MD

A prospective cohort from the Nurses’ Health Study has demonstrated that eating a healthy diet results in a 12% to 32% lower risk of incident gout and an even greater risk reduction (65% to 68%) when combined with normal weight and avoiding diuretics.

Read Article
ACR, guidance, guidelines

ACR Newly Revised COVID-19 Vaccine Clinical Guidance for RMD Patients

d ACR

The ACR has updated its clinical guidance for the use of COVID-19 vaccination in patients with musculoskeletal disorders (MSK). 

Read Article
In the USA, the prevalence of Vitiligo in adults is between 0.76% (1.9 million cases in 2020) and 1.11% (2.8 million cases in 2020). Approximately 40% of adult vitiligo in the US may be undiagnosed. https://t.co/rsyoIbHmS8

Links:

Dr. John Cush RheumNow ( View Tweet)

Radiographic progression in AxSpA studied in 101 Spanish Pts - pts w/ sustained low ASDAS had less XRay progression than those with active Dz (2.33 vs 1.76, p=0.027). Long term TNFi use didnt influence progression until the 3rd Yr https://t.co/KHCdzbqhzr

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA has expanded its approval of REMDESIVIR for use in non-hospitalizedadults and pediatric patients for the treatment of mild-to-moderate COVID-19 disease. Previously, Veklury was limited to hospitalized COVID-19 pts. https://t.co/dHbomchfB5

Links:

Dr. John Cush RheumNow ( View Tweet)

Interested in our most popular articles? Head over to RheumNow. https://t.co/8JLpph3or8

Links:

Dr. John Cush RheumNow ( View Tweet)

Finnish Parkinson’s disease (FINPARK) cohort (22,189) looked at the assoc w/ #RA. RA pts using only chloroquine/hydroxychloroquine was associated with a lower risk of developing PD (adjusted OR 0.74); not with other DMARDs https://t.co/yZhgVT0xLh

Links:

Dr. John Cush RheumNow ( View Tweet)

Systematic review of GI Safety of IL-17 inhibitors included 106 RCTs and 40,053 patients. Inflammatory bowel disease occurred in 0.4%; Most freq Sxs - diarrhea (2.5%), nausea or vomiting (0.7%), and gastroenteritis (0.2%). https://t.co/tv3QXHU1Hg

Links:

Dr. John Cush RheumNow ( View Tweet)

Top Tweet in January Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24. https://t.co/j0BRs9snVH https://t.co/4OTmbNJ2GP

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Live: Shorter Lectures, More Discussion - Rheumatologists like us, go to meetings like this; meetings that matter; meetings that change thinking We have a packed agenda with experts from around the world. https://t.co/94QmsCqSdj https://t.co/DIJrI8hwDa

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of Academic Clinicians showed that for every $1 generated though office visits (E&M coding) by 5 practicing academic rheums, $12.14 were generated through downstream revenue (mostly infusions). https://t.co/YQ1RL5JF9u

Links:

Dr. John Cush RheumNow ( View Tweet)

The US FDA has published a 52 page report entitled, "DRUG SAFETY PRIORITIES 2021" covering, REMS, Sentinal program, Drug safety communications (eg, Xeljanz), nitrosamine impurities (NMDA), opioids, COVID drug safety & more...https://t.co/vcMZqkdsz5

Links:

Dr. John Cush RheumNow ( View Tweet)

We are excited to announce that Dr. Ernest Choy will be joining us at RheumNow Live, leading a presentation on Precision Medicine in Rheumatoid Arthritis. Join the discussion on March 19-20. Invigorate, Instigate and Debate Rheumatology at #RNL2022 https://t.co/4uXQfRvRgc https://t.co/7KcPXadGcY

Links:

Dr. John Cush RheumNow ( View Tweet)
Following a mild bout of COVID-19, Dr. Kathryn Dao, shares insights on the best way to handle mild cases whether it is yourself or a friend/family member who has COVID19. https://t.co/mevbQVNjPp ( @KDAO2011) https://t.co/CSzB9ChH3r

Links:

Dr. John Cush RheumNow ( View Tweet)
Article in JAMA estimates that there are 110,000 LESS deaths per year when US adults aged 40-85 years or older had a modest increase in their modest increases in moderate-to-vigorous physical activity intensity per day (ie, 10 minutes per day) https://t.co/n1ictmjnqi

Links:

Dr. John Cush RheumNow ( View Tweet)

2021 approved Efgartigimod (Vyvgart) for myasthenia gravis: (binds neonatal Fc receptor, stops Ig recirculation): pts w/ AChR Abs respond best (68% vs 30%). Common AEs include URI, UTI, HA; other AE: eyelid swelling, rash, and SOB. https://t.co/wQKZuAlXoR

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: MMWR reports >40,000 pregnant women who received COVID-19 vaccination during pregnancy- VAX not associated with preterm birth or small-for-gestational-age at birth overall compared with unvaccinated pregnant women. https://t.co/GtRMsNrFnn

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×